ADC Therapeutics doses patients in testing ADCT-402, after encouraging safety profile and anti-tumor activity

Oncology drug specialist ADC Therapeutics has continued with its Phase I clinical trial of combination of ADCT-402 (loncastuximab tesirine) with Pharmacyclics LLC’s ibrutinib, by dosing patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).

Read more